Invitae Corporation (NVTAQ)
- Previous Close
0.0090 - Open
0.0004 - Bid --
- Ask --
- Day's Range
0.0004 - 0.0065 - 52 Week Range
0.0001 - 1.6700 - Volume
271,721 - Avg. Volume
8,734,670 - Market Cap (intraday)
143,246 - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.30
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
www.invitae.com1,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVTAQ
Performance Overview: NVTAQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVTAQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVTAQ
Valuation Measures
Market Cap
143.25k
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
2.60
Enterprise Value/EBITDA
-0.98
Financial Highlights
Profitability and Income Statement
Profit Margin
-299.14%
Return on Assets (ttm)
-23.70%
Return on Equity (ttm)
--
Revenue (ttm)
481.58M
Net Income Avi to Common (ttm)
-1.44B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
254.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-34.7M